

**American College of Radiology  
ACR Appropriateness Criteria®  
Staging and Follow-up of Ovarian Cancer**

**Variant 1: Initial staging of pretreatment ovarian cancer.**

Procedure	Appropriateness Category	Relative Radiation Level
CT abdomen and pelvis with IV contrast	Usually Appropriate	⊕⊕⊕
CT chest abdomen pelvis with IV contrast	Usually Appropriate	⊕⊕⊕⊕
FDG-PET/CT skull base to mid-thigh	May Be Appropriate	⊕⊕⊕⊕
MRI abdomen and pelvis without and with IV contrast	May Be Appropriate	○
CT abdomen and pelvis without IV contrast	May Be Appropriate	⊕⊕⊕
CT chest abdomen pelvis without IV contrast	May Be Appropriate	⊕⊕⊕⊕
MRI abdomen and pelvis without IV contrast	May Be Appropriate	○
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	⊕⊕⊕⊕
CT chest abdomen pelvis without and with IV contrast	Usually Not Appropriate	⊕⊕⊕⊕
US abdomen and pelvis transabdominal	Usually Not Appropriate	○
US pelvis transvaginal	Usually Not Appropriate	○
X-ray contrast enema	Usually Not Appropriate	⊕⊕⊕
Radiography intravenous urography	Usually Not Appropriate	⊕⊕⊕

**Variant 2: Extent of disease in suspected or known recurrence of ovarian cancer.**

Procedure	Appropriateness Category	Relative Radiation Level
CT abdomen and pelvis with IV contrast	Usually Appropriate	⊕⊕⊕
CT chest abdomen pelvis with IV contrast	Usually Appropriate	⊕⊕⊕⊕
FDG-PET/CT skull base to mid-thigh	Usually Appropriate	⊕⊕⊕⊕
MRI abdomen and pelvis without and with IV contrast	May Be Appropriate	○
CT abdomen and pelvis without IV contrast	May Be Appropriate	⊕⊕⊕
CT chest abdomen pelvis without IV contrast	May Be Appropriate	⊕⊕⊕⊕
MRI abdomen and pelvis without IV contrast	May Be Appropriate	○
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	⊕⊕⊕⊕
CT chest abdomen pelvis without and with IV contrast	Usually Not Appropriate	⊕⊕⊕⊕
US abdomen and pelvis transabdominal	Usually Not Appropriate	○
US pelvis transvaginal	Usually Not Appropriate	○
X-ray contrast enema	Usually Not Appropriate	⊕⊕⊕
Radiography intravenous urography	Usually Not Appropriate	⊕⊕⊕

## STAGING AND FOLLOW-UP OF OVARIAN CANCER

Expert Panel on Women's Imaging: Stella K. Kang, MD, MS<sup>a</sup>; Caroline Reinhold, MD<sup>b</sup>; Mostafa Atri, MD<sup>c</sup>; Carol B. Benson, MD<sup>d</sup>; Priyadarshani R. Bhosale, MD<sup>e</sup>; Anuja Jhingran, MD<sup>f</sup>; Yulia Lakhman, MD<sup>g</sup>; Katherine E. Maturen, MD, MS<sup>h</sup>; Refky Nicola, DO MSc<sup>i</sup>; Pari V. Pandharipande, MD, MPH<sup>j</sup>; Gloria M. Salazar, MD<sup>k</sup>; Thomas D. Shipp, MD, RDMS<sup>l</sup>; Lynn Simpson, MD<sup>m</sup>; William Small Jr, MD<sup>n</sup>; Betsy L. Sussman, MD<sup>o</sup>; Jennifer W. Uyeda, MD<sup>p</sup>; Darci J. Wall, MD<sup>q</sup>; Bradford P. Whitcomb, MD<sup>r</sup>; Carolyn M. Zelof, MD<sup>s</sup>; Phyllis Glanc, MD.<sup>t</sup>

### **Summary of Literature Review**

#### **Introduction/Background**

Ovarian cancer is the fifth most common cause of cancer death in women in the United States behind lung, breast, colorectal, and pancreatic cancers, accounting for more than 3% of all cancers in women and causing more deaths than any other gynecologic malignancy [1]. Most of the information in this narrative regarding imaging use for staging and evaluation of recurrence applies to epithelial ovarian cancers. Two major subtypes of epithelial ovarian cancers are distinguished by molecular, genetic, and morphologic characteristics: type 1 being the relatively indolent low-grade serous, low-grade endometrioid, mucinous tumors, transitional (Brenner), and clear cell carcinomas; and type 2 being aggressive neoplasms, including high-grade serous or endometrioid, and undifferentiated cancer [2]. The aggressive (type 2) ovarian cancers most often present in advanced stages, stage III-IV, after the disease has spread widely out of the pelvis [3,4]. This document is mostly reflective of staging and follow-up for type 2 ovarian cancers. The major roles of diagnostic imaging have been to characterize the ovarian mass, determine the extent of preoperative disease, predict tumor resectability, and evaluate response to chemotherapy [4-11]. Surgical staging is both diagnostic and therapeutic, and an experienced gynecologic surgeon (a gynecologic oncologist, specifically) is critical in optimum debulking of this tumor [9,12,13]. However, up to 40% of patients may be understaged at laparotomy [14], and prognosis is tied to the presence of residual tumor after surgery.

#### **CA-125 Levels**

The preoperative evaluation of patients with suspected ovarian carcinoma usually includes a serum (cancer antigen) CA-125 determination. Only about 50% of all patients with stage I ovarian cancer have a true-positive result [4,15-17]. Thus, this test alone is inadequate when used in isolation as a screening tool. This is especially true in menstruating females, since false-positive results have been reported with endometriosis, benign ovarian cysts, pregnancy, and pelvic inflammatory disease. Pancreatic cancer and cirrhosis may also result in elevated CA-125 levels [18]. However, with stage II or greater ovarian cancer, the true-positive rate is as high as 80% [16]. There is a very high correlation between CA-125 levels and the clinical course of the patient during chemotherapy. CA-125 levels also can be used to predict tumor recurrence in patients who are clinically tumor free [19]. Oftentimes, other epithelial and nonepithelial tumor markers are ordered to differentiate tumor histology preoperatively. CA19-9 and carcinoembryogenic antigen (CEA) can also be elevated with epithelial ovarian neoplasms, but have limited specificity individually, and a high CA125-to-CEA ratio has been shown to optimize specificity for ovarian versus gastrointestinal primary neoplasms [20,21].

#### **Overview of Imaging Modalities**

Imaging is used to detect and characterize adnexal masses and to stage ovarian cancer both prior to and following initial treatment. Thus far, no imaging method has achieved a sufficiently high positive predictive value to be recommended for screening women of average risk [4]; please see the ACR Appropriateness Criteria<sup>®</sup> "[Ovarian](#)

<sup>a</sup>Principal Author, New York University Medical Center, New York, New York. <sup>b</sup>Panel Chair, McGill University, Montreal, Quebec, Canada. <sup>c</sup>Toronto General Hospital, Toronto, Ontario, Canada. <sup>d</sup>Brigham & Women's Hospital, Boston, Massachusetts. <sup>e</sup>University of Texas MD Anderson Cancer Center, Houston, Texas. <sup>f</sup>University of Texas MD Anderson Cancer Center, Houston, Texas. <sup>g</sup>Memorial Sloan Kettering Cancer Center, New York, New York. <sup>h</sup>University of Michigan, Ann Arbor, Michigan. <sup>i</sup>State University of New York Upstate Medical University, Syracuse, New York. <sup>j</sup>Massachusetts General Hospital, Boston, Massachusetts. <sup>k</sup>Massachusetts General Hospital, Boston, Massachusetts. <sup>l</sup>Brigham & Women's Hospital, Boston, Massachusetts; American Congress of Obstetricians and Gynecologists. <sup>m</sup>Columbia University, New York, New York; American Congress of Obstetricians and Gynecologists. <sup>n</sup>Stritch School of Medicine Loyola University Chicago, Maywood, Illinois. <sup>o</sup>The University of Vermont Medical Center, Burlington, Vermont. <sup>p</sup>Brigham & Women's Hospital, Boston, Massachusetts. <sup>q</sup>Mayo Clinic, Rochester, Minnesota. <sup>r</sup>Tripler Army Medical Center, Honolulu, Hawaii; Society of Gynecologic Oncology. <sup>s</sup>Valley Hospital, Ridgewood, New Jersey and NYU School of Medicine, New York, New York; American Congress of Obstetricians and Gynecologists. <sup>t</sup>Specialty Chair, University of Toronto and Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: [publications@acr.org](mailto:publications@acr.org)

[Cancer Screening](#)” [22] for further discussion. In patients at increased risk for ovarian carcinoma based on hereditary factors or serum markers, transvaginal ultrasound (US) may be used for ovarian cancer screening, although determinations of outcome-based benefits are still preliminary at best [4,22-28]. Characterization of adnexal masses is not in the scope of this topic, please see the ACR Appropriateness Criteria® “[Clinically Suspected Adnexal Mass](#)” [29] for further discussion. Briefly, transvaginal US is also useful for determining the site of origin of a pelvic mass and to characterize the lesion [30]. A combination of morphology on transvaginal US and Doppler waveform analysis may provide an accurate risk assessment for adnexal lesions [8,23]. Magnetic resonance imaging (MRI) is excellent for characterizing adnexal masses that are indeterminate by US [6-8,31-33]. Positron emission tomography (PET) using the tracer fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG), particularly when combined with computed tomography (CT), has improved the accuracy of staging ovarian carcinoma [10,32,34-37]. PET combined with MRI is a newer modality, for which a specific role has not yet been established [38].

The decision regarding initial treatment for ovarian cancer depends on accurate staging. CT, FDG-PET/CT, and MRI have been used to assess the resectability of tumors, the candidacy of patients for effective cytoreductive surgery, the need for postoperative chemotherapy if debulking is suboptimal, and the need for referral to a gynecologic oncologist [5,34-36,39-45]. Referral to a gynecologic oncologist for optimal staging and debulking is the second most important determinant for survival after tumor stage in patients with ovarian carcinoma. The International Federation of Gynecologists and Obstetricians revised the criteria for ovarian cancer staging in 2014 [46]. The updated system recognizes the morphologic and molecular similarities between fallopian tube, primary peritoneal carcinomas, and ovarian malignancy [47]. Stage I disease includes tumor limited to 1 or both ovaries or fallopian tubes, stage II disease has spread to the surface of other pelvic organs, stage III indicates spread to retroperitoneal lymph nodes (IIIA1) or abdominal peritoneal surfaces (IIIA2 if microscopic disease, IIIB or C with macroscopic nodules), and stage IV is advanced disease with distant metastases to solid organs or a malignant pleural effusion [5,6,46]. When there is a contraindication to administration of iodinated contrast, CT without intravenous contrast offers limited evaluation of extent of disease in initial evaluation or follow-up; for more information on the imaging of patients with end-stage renal failure, please see the ACR Manual on Contrast Media [48].

Cytoreductive surgery is the standard initial treatment for ovarian cancer. Imaging is used to define the extent of disease, assess the likelihood of optimal primary cytoreduction [14], and select patients who may benefit from neoadjuvant chemotherapy [49,50]. The radiographic techniques for preoperative staging of ovarian cancer called for by the International Federation of Gynecology and Obstetrics—such as chest radiograph, barium enema, and excretory urography—have been replaced by more advanced cross-sectional imaging techniques such as CT [51-53] in the United States and many other countries. The accuracy of imaging for prediction of suboptimal debulking, and therefore patient selection for surgical versus neoadjuvant treatment, remains controversial [54-56].

## **Discussion of Procedures by Variant**

### **Variant 1: Initial staging of pretreatment ovarian cancer.**

#### **CT Abdomen and Pelvis**

Contrast-enhanced CT (with oral contrast) is the current imaging modality of choice in the preoperative evaluation of ovarian cancer and is an accurate method for identifying sites of abdominopelvic disease that predict successful surgical cytoreduction [57]. CT has been useful to detect local tumor involvement of the pelvic ureter and uterine serosa (although uterine serosal involvement is less important in ovarian cancer than it is for endometrial cancer), as well as metastases to the peritoneum, omentum, mesentery, liver, spleen, lymph nodes, and lung parenchyma [5,39,40,52]. CT has a reported accuracy for ovarian cancer staging of up to 94% [14]. The sensitivity varies by anatomic site, however, and the most important limitation of CT in staging ovarian cancer is its inability to reliably detect bowel surface, mesenteric, or peritoneal tumor implants <5 mm, especially in the absence of ascites [5,43,58,59]. CT is also useful for guiding biopsy of the omentum, or other abdominal tumor, a procedure that can increase the accuracy of preoperative diagnosis, if indicated [60-63].

For assessment of the resectability of ovarian cancer, cross-sectional imaging (CT or MRI) plays a critically important role in finding significant lesions (>2 cm) at the root of the mesentery, gastrosplenic ligament, omentum of the lesser sac, porta hepatis, intersegmental fissure of the liver, diaphragm, liver dome, and lung parenchyma, and also in detecting lymphadenopathy at or above the celiac axis, presacral extraperitoneal disease, and pelvic sidewall invasion [5,14,40,52,64-68]. Incomplete resection (residual tumor >1 cm) of primary tumor

yields little survival benefit while subjecting patients to substantial perioperative morbidity. To date, imaging and prediction models that are based on imaging, demographic characteristics, and tumor markers have not been shown to provide sufficiently high accuracy for prediction of suboptimal debulking to guide the decision regarding surgery [55,69]. Unresectable disease can be managed by needle or laparoscopic biopsy, followed by chemotherapy, and possibly by a later attempt at interval debulking, resulting in improved survival by virtue of response to chemotherapy and optimal resection [9,34,60-63].

Noncontrast-enhanced CT of the abdomen and pelvis offers limited ability to differentiate small peritoneal or mesenteric implants, or lymphadenopathy, from bowel or other adjacent organs.

### **CT Chest**

CT of the chest is useful for detecting pleural and pulmonary metastases during primary staging. Although CT is not sensitive for detecting pleural metastases, these can be verified by video-assisted thoracoscopy, if needed [70]. Preoperative detection by CT of a moderate-to-large pleural effusion helps predict poor post-treatment outcome [71]. For postsurgical surveillance, the yield of chest CT is low if the chest radiograph shows no abnormalities, CT shows no abdominal or pelvic disease, and there is no rising serum CA-125 [72,73]. If PET using tracer FDG is used and includes chest, abdomen, and pelvis, the added value of diagnostic-quality chest CT is probably even lower.

### **MRI**

MRI is an excellent problem-solving technique by virtue of its ability to define common conditions such as fibroids, dermoid cysts, endometriomas, and other benign lesions [6-8,31,44]. A multivariable analysis showed that the accuracy of MRI with gadolinium enhancement in separating ovarian malignancy from other types of adnexal masses was 93% [74]. Gadolinium enhancement and diffusion-weighted imaging offer improved diagnostic confidence and tissue characterization [31,74]. In staging, MRI has been shown to provide equivalent accuracy to CT and to predict peritoneal tumor volume comparable with surgery, with sensitivity of 0.88, specificity of 0.74, and accuracy of 0.84 [75,76]. However, the role of MRI in staging has been limited because 1) the use of intraluminal gastrointestinal contrast agents with MRI is not routine as it is with CT, and 2) patient motion is a greater problem for MRI than for CT. Although CT is currently the modality of choice for staging ovarian cancer, MRI is recommended for patients with borderline tumors or ovarian cancers that have been previously staged with fertility preservation (to minimize ionizing radiation exposure), or for some patients whose CT findings are inconclusive [68,77]. Higher-field MRI scans may improve the accuracy of MRI for staging ovarian cancer pending further investigation [78].

Intravenous contrast is preferable for detection and characterization of lesions suspected to represent tumor deposits. MRI without contrast may be considered for staging if contrast cannot be given and may offer improved soft-tissue contrast than noncontrast CT for staging in the pelvis; however, to our knowledge, there are no known studies on the comparative performance of MRI without contrast and CT without contrast for staging.

### **FDG-PET/CT**

The use of FDG-PET imaging in the primary diagnosis and tissue characterization of ovarian cancer is unsupported to date. Specificity has been reported to be as low as 54%, while sensitivity has been as high as 86% [33,79,80]. Also, false-negative results have been reported with borderline tumors, mucinous tumors, early carcinomas, and other low-grade types of tumors [81,82]. False-positive results have been reported with fibromas, dermoid cysts, hydrosalpinges, and endometriosis [68,80].

However, FDG-PET, especially when combined with CT, is a valuable tool for diagnosing and staging advanced disease [32,34-37,79]. For staging, fusion FDG-PET/CT has higher reported accuracy than either CT or FDG-PET alone in multiple studies [32,35,36,79,83]. Improved detection of peritoneal disease may stem from metabolic activity in small deposits or lymph nodes that may be difficult to identify and characterize with CT alone. Thus, although CT with contrast is the modality of choice for initial staging, PET or FDG-PET/CT may be a useful adjunct test, particularly when CT is indeterminate.

### **Contrast Enema**

Contrast enema is not routinely used for pretreatment staging of ovarian cancer. An exception may occur when there is concern about the possibility of a colonic primary versus ovarian primary malignancy based on preoperative CT findings, signs, symptoms, and CA-125 and CEA tumor marker ratio.

## **IVU**

Intravenous urography (IVU) is not routinely used for pretreatment staging of ovarian cancer.

## **US**

There is no evidence to support a role for US in initial staging evaluation of ovarian cancer. Transvaginal US is mainly useful for determining the site of origin of a pelvic mass and to characterize the lesion [30].

### **Variants 2: Extent of disease in suspected or known recurrence of ovarian cancer.**

Imaging of the chest, abdomen, and pelvis plays a key role in evaluation for recurrence and the extent of disease. Rising CA-125, symptoms, or other clinical suspicion for relapse after treatment prompts imaging evaluation for recurrence. If imaging or clinical examination confirms a recurrent tumor, the extent of disease and timing of disease recurrence then determines the choice(s) of treatments, including surgery, chemotherapy, and radiation therapy. The choices for treatment depend upon the time that has passed since chemotherapy was completed. In general, surgical resection of the recurrent tumor is an option when chemotherapy was completed more than 6 months before recurrence and with the option for additional radiation therapy or chemotherapy after surgery.

The role for routine surveillance with imaging is unclear in patients considered to be in clinical remission. Imaging has been shown to have limited sensitivity for detection of small tumor deposits in the abdomen and pelvis, with or without monitoring of CA-125 [3,84]. Furthermore, the MRC OV05/EORTC trial did not show a difference in overall survival when patients were treated based on elevated CA-125 versus clinical evidence of recurrence (including imaging findings) [85], despite recognition that CA-125 is generally elevated in cases of recurrence before clinical or imaging signs become evident. The National Comprehensive Cancer Network guidelines for follow-up of primary chemotherapy with complete response include imaging tests as needed, using CT, FDG-PET, FDG-PET/CT, MRI, or chest radiographs [11].

## **CT**

Contrast-enhanced CT (also using oral contrast) is the modality of choice for detecting recurrence in the chest, abdomen, or pelvis. Contrast-enhanced CT has a reported sensitivity ranging from 58% to 84% and specificity in the range of 59% to 100% in identifying tumor recurrence [52,86,87]. Recurrent disease usually manifests as peritoneal implants; within the peritoneal cavity and on the surface of the visceral organs. CT is used to identify tumor deposits in the root of the mesentery, gastrosplenic ligament, omentum of the lesser sac, porta hepatis, intersegmental fissure of the liver, diaphragm, liver dome, and lung parenchyma, and also in detecting lymphadenopathy. However, identification of small (<5 mm) tumor deposits in the mesentery, on bowel wall, or along the peritoneum may be limited [5,43,58,59].

Noncontrast-enhanced CT of the abdomen and pelvis offers limited ability to identify small peritoneal or mesenteric implants, or lymphadenopathy among bowel loops and other adjacent organs.

## **MRI**

The reported accuracy of MRI for detecting lesions >2 cm in recurrent disease is comparable to that of CT at 93% to 95% [14]. However, MRI demonstrated a significantly lower area under the receiver operator characteristic curve than CT, FDG-PET, FDG-PET/CT, or CA-125 for overall detection of recurrent ovarian cancer in a meta-analysis [88]. CT remains the most widely used imaging method for detecting recurrence, and, despite some advantages, the role of MRI in follow-up imaging has been limited because 1) the use of intraluminal gastrointestinal contrast agents with MRI is not routine as it is with CT and 2) patient motion is a greater problem for MRI than for CT. Although CT is currently the modality of choice for suspected recurrence of ovarian cancer, MRI is recommended for borderline tumors or ovarian cancers that have been previously staged with fertility preservation (to minimize ionizing radiation exposure), or for some patients whose CT findings are inconclusive.

Intravenous contrast is preferable for detection and characterization of lesions suspected to represent tumor deposits. MRI without contrast may be considered for staging if contrast cannot be given and may offer improved soft-tissue contrast than noncontrast CT for staging in the pelvis. However, to our knowledge, there are no known studies on the comparative performance of MRI without contrast and CT without contrast for staging.

## **FDG-PET/CT**

For suspected recurrent ovarian cancer, FDG-PET/CT has recently shown similar or higher accuracy for tumor detection than contrast-enhanced CT or PET alone [10,19,34,89,90], with a sensitivity of 95% to 97% and specificity of 80% to 100% [86,89,91]. The spatial resolution of PET limits sensitivity for subcentimeter metastases, and metabolic activity on or between bowel loops, particularly after surgery when adhesions or

inflammation are present, may be difficult to assess. For such reasons, PET or FDG-PET/CT has not uniformly shown improved sensitivity or specificity of recurrence compared with CT alone [88]. Still, the combined metabolic activity and anatomic localization of FDG-PET/CT have been shown to improve disease detection in small lymph nodes and unresectable sites, which can alter management [87,91]. Notably, the performance of FDG-PET/CT in the literature reflects a predominance of serous papillary carcinomas, and false-negative results have been reported with mucinous adenocarcinomas, and cystic, necrotic, low-grade or small-volume (<7 mm) deposits [82]. Thus, either CT or FDG-PET/CT may be used to evaluate suspected recurrence, and FDG-PET/CT may also be a useful adjunct when CT is indeterminate with persistent clinical concern [92].

### **Contrast Enema**

Contrast enema is not routinely used for detecting recurrence of ovarian cancer.

### **IVU**

IVU is not routinely used for detecting recurrence of ovarian cancer.

### **Laparotomy**

Second-look laparotomy is no longer routinely performed because the noninvasive diagnosis of recurrence obviates the need for unnecessary surgery, and generally may be reserved for patients in which the second-look findings might change treatment planning or clinical trial protocols [93]. The decision for secondary debulking surgery is guided by a chemotherapy-free interval, patient performance status, and extent and resectability of disease at time of recurrence. Imaging therefore plays a critical role in the decision-making process for secondary debulking [94].

### **US**

US is not routinely used for detection of recurrent ovarian cancer after surgery. In cases of borderline ovarian tumors (or invasive malignancies) in which fertility-sparing surgery has been performed, transvaginal US has been used in surveillance of the adnexa for recurrent lesions [95].

### **Summary of Recommendations**

- For the initial staging of ovarian cancer, contrast-enhanced CT (with oral contrast) of the abdomen and pelvis is the imaging modality of choice, with inclusion of the chest where indicated. These examinations are complementary and should be performed together.
- Contrast-enhanced CT of the abdomen and pelvis (with oral contrast), or CT of the chest, abdomen, and pelvis are the modalities of choice for the extent of disease in suspected recurrence, and FDG-PET/CT is also usually appropriate as it can provide management-changing information about unresectable sites of tumor or small lymph nodes. CT and FDG-PET/CT are considered equivalent alternatives.

### **Summary of Evidence**

Of the 96 references cited in the *ACR Appropriateness Criteria® Staging and Follow-up of Ovarian Cancer* document, 5 are categorized as therapeutic references including 4 good-quality studies. Additionally, 88 references are categorized as diagnostic references including 1 well-designed study, 25 good-quality studies, and 35 quality studies that may have design limitations. There are 28 references that may not be useful as primary evidence. There are 3 references that are meta-analysis studies.

The 96 references cited in the *ACR Appropriateness Criteria® Staging and Follow-up of Ovarian Cancer* document were published from 1986-2017.

Although there are references that report on studies with design limitations, 30 well-designed or good-quality studies provide good evidence.

## Appropriateness Category Names and Definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel's recommendation. "May be appropriate" is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

## Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document [96].

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
○	0 mSv	0 mSv
⊗	<0.1 mSv	<0.03 mSv
⊗⊗	0.1-1 mSv	0.03-0.3 mSv
⊗⊗⊗	1-10 mSv	0.3-3 mSv
⊗⊗⊗⊗	10-30 mSv	3-10 mSv
⊗⊗⊗⊗⊗	30-100 mSv	10-30 mSv

\*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as "Varies".

## Supporting Documents

For additional information on the Appropriateness Criteria methodology and other supporting documents go to [www.acr.org/ac](http://www.acr.org/ac).

## References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin.* 2017;67(1):7-30.
2. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. *Am J Surg Pathol.* 2010;34(3):433-443.
3. Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. *Int J Gynecol Cancer.* 2009;19(3):367-374.
4. Lutz AM, Willmann JK, Drescher CW, et al. Early diagnosis of ovarian carcinoma: is a solution in sight? *Radiology.* 2011;259(2):329-345.
5. Chandrashekhara SH, Thulkar S, Srivastava DN, et al. Pre-operative evaluation of peritoneal deposits using multidetector computed tomography in ovarian cancer. *Br J Radiol.* 2011;84(997):38-43.
6. Jeong YY, Outwater EK, Kang HK. Imaging evaluation of ovarian masses. *Radiographics.* 2000;20(5):1445-1470.
7. Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. *Radiographics.* 2002;22(6):1305-1325.
8. Liu J, Xu Y, Wang J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. *Eur J Radiol.* 2007;62(3):328-334.
9. Rettenmaier NB, Rettenmaier CR, Wojciechowski T, et al. The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review. *Br J Cancer.* 2010;103(11):1657-1662.
10. Son H, Khan SM, Rahaman J, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. *Radiographics.* 2011;31(2):569-583.
11. NCCN Clinical Practice Guidelines in Oncology. Epithelial Ovarian Cancer (including Fallopian Tube Cancer and Primary Peritoneal Cancer). Version 3.2017. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/ovarian.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf). Accessed March 30, 2018.
12. Chi DS, Barlin JN, Ramirez PT, et al. Follow-up study of the correlation between postoperative computed tomographic scan and primary surgeon assessment in patients with advanced ovarian, tubal, or peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease of 1 cm or smaller. *Int J Gynecol Cancer.* 2010;20(3):353-357.
13. Risum S, Hogdall C, Loft A, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study. *Gynecol Oncol.* 2008;108(2):265-270.
14. Forstner R, Hricak H, Occhipinti KA, Powell CB, Frankel SD, Stern JL. Ovarian cancer: staging with CT and MR imaging. *Radiology.* 1995;197(3):619-626.
15. Azad NS, Annunziata CM, Steinberg SM, et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. *Cancer.* 2008;112(8):1726-1732.
16. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. *Bmj.* 1993;306(6884):1030-1034.
17. Kim HS, Kim JW, Cho JY, et al. The role of serum CA-125 levels in early-stage epithelial ovarian cancer on preoperative CT and MRI. *Eur J Surg Oncol.* 2009;35(8):870-876.
18. Haglund C. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. *Br J Cancer.* 1986;54(6):897-901.
19. Murakami M, Miyamoto T, Iida T, et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. *Int J Gynecol Cancer.* 2006;16 Suppl 1:99-107.
20. Kelly PJ, Archbold P, Price JH, Cardwell C, McCluggage WG. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. *J Clin Pathol.* 2010;63(2):169-173.
21. Yedema CA, Kenemans P, Wobbes T, et al. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. *Tumour Biol.* 1992;13(1-2):18-26.
22. American College of Radiology. ACR Appropriateness Criteria®: Ovarian Cancer Screening. Available at: <https://acsearch.acr.org/docs/69463/Narrative/>. Accessed March 30, 2018.
23. Kinkel K, Hricak H, Lu Y, Tsuda K, Filly RA. US characterization of ovarian masses: a meta-analysis. *Radiology.* 2000;217(3):803-811.

24. Twickler DM, Moschos E. Ultrasound and assessment of ovarian cancer risk. *AJR Am J Roentgenol*. 2010;194(2):322-329.
25. Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, van Nagell JR, Jr. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. *Gynecol Oncol*. 2003;91(1):46-50.
26. van Nagell JR, Jr., DePriest PD, Ueland FR, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. *Cancer*. 2007;109(9):1887-1896.
27. Yazbek J, Ameye L, Testa AC, et al. Confidence of expert ultrasound operators in making a diagnosis of adnexal tumor: effect on diagnostic accuracy and interobserver agreement. *Ultrasound Obstet Gynecol*. 2010;35(1):89-93.
28. Yazbek J, Raju SK, Ben-Nagi J, Holland TK, Hillaby K, Jurkovic D. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial. *Lancet Oncol*. 2008;9(2):124-131.
29. American College of Radiology. ACR Appropriateness Criteria®: Clinically Suspected Adnexal Mass. Available at: <https://acsearch.acr.org/docs/69466/Narrative/>. Accessed March 30, 2018.
30. Conway C, Zalud I, Dilena M, et al. Simple cyst in the postmenopausal patient: detection and management. *J Ultrasound Med*. 1998;17(6):369-372; quiz 373-364.
31. Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study. *AJR Am J Roentgenol*. 2009;193(2):461-470.
32. Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. *Gynecol Oncol*. 2010;116(3):389-394.
33. Rieber A, Nussle K, Stohr I, et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. *AJR Am J Roentgenol*. 2001;177(1):123-129.
34. Fagotti A, Fanfani F, Rossitto C, et al. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy. *Oncology*. 2008;75(3-4):152-158.
35. Kitajima K, Murakami K, Yamasaki E, et al. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. *Eur J Nucl Med Mol Imaging*. 2008;35(10):1912-1920.
36. Pfannenbergl C, Konigsrainer I, Aschoff P, et al. (18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol*. 2009;16(5):1295-1303.
37. Risum S, Hogdall C, Loft A, et al. Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? *Gynecol Oncol*. 2010;116(3):395-398.
38. Grueneisen J, Beiderwellen K, Heusch P, et al. Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis: a comparison to whole-body magnetic resonance imaging alone. *Invest Radiol*. 2014;49(12):808-815.
39. Akin O, Sala E, Moskowitz CS, et al. Perihepatic metastases from ovarian cancer: sensitivity and specificity of CT for the detection of metastases with and those without liver parenchymal invasion. *Radiology*. 2008;248(2):511-517.
40. Kolev V, Mironov S, Mironov O, et al. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer. *Int J Gynecol Cancer*. 2010;20(6):979-984.
41. Thomassin-Naggara I, Bazot M, Darai E, Callard P, Thomassin J, Cuenod CA. Epithelial ovarian tumors: value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. *Radiology*. 2008;248(1):148-159.
42. Buy JN, Ghossain MA, Sciote C, et al. Epithelial tumors of the ovary: CT findings and correlation with US. *Radiology*. 1991;178(3):811-818.
43. Ghossain MA, Buy JN, Ligneres C, et al. Epithelial tumors of the ovary: comparison of MR and CT findings. *Radiology*. 1991;181(3):863-870.
44. Semelka RC, Lawrence PH, Shoenut JP, Heywood M, Kroeker MA, Lotocki R. Primary ovarian cancer: prospective comparison of contrast-enhanced CT and pre- and postcontrast, fat-suppressed MR imaging, with histologic correlation. *J Magn Reson Imaging*. 1993;3(1):99-106.

45. Qayyum A, Coakley FV, Westphalen AC, Hricak H, Okuno WT, Powell B. Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer. *Gynecol Oncol.* 2005;96(2):301-306.
46. Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. *Gynecol Oncol.* 2014;133(3):401-404.
47. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? *Am J Surg Pathol.* 2010;34(10):1407-1416.
48. American College of Radiology. *Manual on Contrast Media.* Available at: <http://www.acr.org/Quality-Safety/Resources/Contrast-Manual>. Accessed March 30, 2018.
49. Hou JY, Kelly MG, Yu H, et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. *Gynecol Oncol.* 2007;105(1):211-217.
50. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P. Interval debulking surgery for advanced epithelial ovarian cancer: a Cochrane systematic review. *Gynecol Oncol.* 2009;112(1):257-264.
51. Lund B, Jacobsen K, Rasch L, Jensen F, Olesen K, Feldt-Rasmussen K. Correlation of abdominal ultrasound and computed tomography scans with second- or third-look laparotomy in patients with ovarian carcinoma. *Gynecol Oncol.* 1990;37(2):279-283.
52. Meyer JJ, Kennedy AW, Friedman R, Ayoub A, Zepp RC. Ovarian carcinoma: value of CT in predicting success of debulking surgery. *AJR Am J Roentgenol.* 1995;165(4):875-878.
53. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. *J Clin Oncol.* 1993;11(1):166-172.
54. Kebapci M, Akca AK, Yalcin OT, Ozalp SS, Calisir C, Mutlu F. Prediction of suboptimal cytoreduction of epithelial ovarian carcinoma by preoperative computed tomography. *Eur J Gynaecol Oncol.* 2010;31(1):44-49.
55. Rutten IJ, van de Laar R, Kruitwagen RF, et al. Prediction of incomplete primary debulking surgery in patients with advanced ovarian cancer: An external validation study of three models using computed tomography. *Gynecol Oncol.* 2016;140(1):22-28.
56. Suidan RS, Ramirez PT, Sarasohn DM, et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. *Gynecol Oncol.* 2014;134(3):455-461.
57. Schmidt S, Meuli RA, Ahtari C, Prior JO. Peritoneal carcinomatosis in primary ovarian cancer staging: comparison between MDCT, MRI, and 18F-FDG PET/CT. *Clin Nucl Med.* 2015;40(5):371-377.
58. Pannu HK, Horton KM, Fishman EK. Thin section dual-phase multidetector-row computed tomography detection of peritoneal metastases in gynecologic cancers. *J Comput Assist Tomogr.* 2003;27(3):333-340.
59. Hynninen J, Kempainen J, Lavonius M, et al. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer. *Gynecol Oncol.* 2013;131(2):389-394.
60. Griffin N, Grant LA, Freeman SJ, et al. Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? *Eur Radiol.* 2009;19(1):230-235.
61. Hewitt MJ, Anderson K, Hall GD, et al. Women with peritoneal carcinomatosis of unknown origin: Efficacy of image-guided biopsy to determine site-specific diagnosis. *Bjog.* 2007;114(1):46-50.
62. Souza FF, Morteale KJ, Cibas ES, Erturk SM, Silverman SG. Predictive value of percutaneous imaging-guided biopsy of peritoneal and omental masses: results in 111 patients. *AJR Am J Roentgenol.* 2009;192(1):131-136.
63. Spencer JA, Weston MJ, Saidi SA, Wilkinson N, Hall GD. Clinical utility of image-guided peritoneal and omental biopsy. *Nat Rev Clin Oncol.* 2010;7(11):623-631.
64. Axtell AE, Lee MH, Bristow RE, et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. *J Clin Oncol.* 2007;25(4):384-389.
65. Megibow AJ, Bosniak MA, Ho AG, Beller U, Hulnick DH, Beckman EM. Accuracy of CT in detection of persistent or recurrent ovarian carcinoma: correlation with second-look laparotomy. *Radiology.* 1988;166(2):341-345.
66. Reuter KL, Griffin T, Hunter RE. Comparison of abdominopelvic computed tomography results and findings at second-look laparotomy in ovarian carcinoma patients. *Cancer.* 1989;63(6):1123-1128.
67. Silverman PM, Osborne M, Dunnick NR, Bandy LC. CT prior to second-look operation in ovarian cancer. *AJR Am J Roentgenol.* 1988;150(4):829-832.

68. Woodward PJ, Hosseinzadeh K, Saenger JS. From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. *Radiographics*. 2004;24(1):225-246.
69. MacKintosh ML, Rahim R, Rajashanker B, et al. CT scan does not predict optimal debulking in stage III-IV epithelial ovarian cancer: a multicentre validation study. *J Obstet Gynaecol*. 2014;34(5):424-428.
70. Cohen-Mouly S, Badia A, Bats AS, et al. Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion. *Int J Gynecol Cancer*. 2009;19(9):1662-1665.
71. Mironov O, Ishill NM, Mironov S, et al. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. *Radiology*. 2011;258(3):776-784.
72. Dachman AH, Visweswaran A, Battula R, Jameel S, Waggoner SE. Role of chest CT in the follow-up of ovarian adenocarcinoma. *AJR Am J Roentgenol*. 2001;176(3):701-705.
73. Sella T, Rosenbaum E, Edelmann DZ, Agid R, Bloom AI, Libson E. Value of chest CT scans in routine ovarian carcinoma follow-up. *AJR Am J Roentgenol*. 2001;177(4):857-859.
74. Hricak H, Chen M, Coakley FV, et al. Complex adnexal masses: detection and characterization with MR imaging--multivariate analysis. *Radiology*. 2000;214(1):39-46.
75. Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. *Ann Surg Oncol*. 2012;19(5):1394-1401.
76. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group. *Radiology*. 2000;215(3):761-767.
77. Mironov S, Akin O, Pandit-Taskar N, Hann LE. Ovarian cancer. *Radiol Clin North Am*. 2007;45(1):149-166.
78. Booth SJ, Turnbull LW, Poole DR, Richmond I. The accurate staging of ovarian cancer using 3T magnetic resonance imaging--a realistic option. *Bjog*. 2008;115(7):894-901.
79. Castellucci P, Perrone AM, Picchio M, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. *Nucl Med Commun*. 2007;28(8):589-595.
80. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. *Radiology*. 2002;223(3):780-788.
81. Alessi A, Martinelli F, Padovano B, et al. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results. *Tumori*. 2016;102(1):103-107.
82. Tanizaki Y, Kobayashi A, Shiro M, et al. Diagnostic value of preoperative SUVmax on FDG-PET/CT for the detection of ovarian cancer. *Int J Gynecol Cancer*. 2014;24(3):454-460.
83. Yoshida Y, Kurokawa T, Kawahara K, et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. *AJR Am J Roentgenol*. 2004;182(1):227-233.
84. Sala E, Mannelli L, Yamamoto K, et al. The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer. *Int J Gynecol Cancer*. 2011;21(2):296-301.
85. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. *Lancet*. 2010;376(9747):1155-1163.
86. Kitajima K, Murakami K, Yamasaki E, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. *Eur J Nucl Med Mol Imaging*. 2008;35(8):1439-1448.
87. Tawakol A, Abdelhafez YG, Osama A, Hamada E, El Refaei S. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy. *Nucl Med Commun*. 2016;37(5):453-460.
88. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. *Eur J Radiol*. 2009;71(1):164-174.
89. Sebastian S, Lee SI, Horowitz NS, et al. PET-CT vs. CT alone in ovarian cancer recurrence. *Abdom Imaging*. 2008;33(1):112-118.
90. Nakamoto Y, Saga T, Ishimori T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. *AJR Am J Roentgenol*. 2001;176(6):1449-1454.
91. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. *Gynecol Oncol*. 2007;105(1):17-22.
92. Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. *Am J Obstet Gynecol*. 2011;204(6):466-478.

93. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. *Gynecol Oncol*. 1994;55(3 Pt 2):S4-14.
94. Suh DH, Kim HS, Chang SJ, Bristow RE. Surgical management of recurrent ovarian cancer. *Gynecol Oncol*. 2016;142(2):357-367.
95. Franchi D, Boveri S, Fruscio R, et al. Imaging in gynecological disease (8): ultrasound characteristics of recurrent borderline ovarian tumors. *Ultrasound Obstet Gynecol*. 2013;41(4):452-458.
96. American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: <https://www.acr.org/-/media/ACR/Files/Appropriateness-Criteria/RadiationDoseAssessmentIntro.pdf>. Accessed March 30, 2018.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.